key: cord-0915184-tdrz5ed8
authors: Alameh, Mohamad-Gabriel; Tombácz, István; Bettini, Emily; Lederer, Katlyn; Sittplangkoon, Chutamath; Wilmore, Joel R.; Gaudette, Brian T.; Soliman, Ousamah Y.; Pine, Matthew; Hicks, Philip; Manzoni, Tomaz B.; Knox, James J.; Johnson, John L.; Laczkó, Dorottya; Muramatsu, Hiromi; Davis, Benjamin; Meng, Wenzhao; Rosenfeld, Aaron M.; Strohmeier, Shirin; Lin, Paulo J.C.; Mui, Barbara L.; Tam, Ying K.; Karikó, Katalin; Jacquet, Alain; Krammer, Florian; Bates, Paul; Cancro, Michael P.; Weissman, Drew; Luning Prak, Eline T.; Allman, David; Locci, Michela; Pardi, Norbert
title: Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses
date: 2021-11-04
journal: Immunity
DOI: 10.1016/j.immuni.2021.11.001
sha: 6250082a287e7444afb9410b98c0c5d5d833a367
doc_id: 915184
cord_uid: tdrz5ed8

Adjuvants are critical for improving the quality and magnitude of adaptive immune responses to vaccination. Lipid nanoparticle (LNP)-encapsulated nucleoside-modified mRNA vaccines have shown great efficacy against SARS-CoV-2, but the mechanism of action of this vaccine platform is not well-characterized. Using influenza virus and SARS-CoV-2 mRNA and protein subunit vaccines, we demonstrated that our LNP formulation has intrinsic adjuvant activity that promotes the induction of strong T follicular helper cell, germinal center B cell, long-lived plasma cell and memory B cell responses that are associated with durable and protective antibodies in mice. Comparative experiments demonstrated that this LNP outperformed a widely used MF59-like adjuvant, AddaVax™. The adjuvant activity of the LNP relies on the ionizable lipid component and on IL-6 cytokine induction, but not on MyD88- or MAVS-dependent sensing of LNPs. Our study identified LNPs as a versatile adjuvant that enhances the efficacy of both traditional and next-generation vaccine platforms.

Vaccines are essential to prevent or control infectious disease outbreaks, often through the induction of protective antibody (Ab) responses (Iwasaki, 2016) . The process leading to the generation of high-affinity Abs occurs in germinal centers (GCs) of secondary lymphoid organs (Victora and Nussenzweig, 2012) . In GCs, B cells undergo somatic hypermutation (SHM) of B cell receptor genes, which is followed by positive selection of high-affinity GC B cells. Ultimately, GC B cells differentiate into high-affinity memory B cells (MBCs) and Ab-secreting long-lived plasma cells (LLPCs) (Griffiths et al., 1984; McKean et al., 1984; Weigert et al., 1970) . T follicular helper (Tfh) cells are a subset of CD4 + T cells specialized in regulating affinity maturation of B cells in GCs (Crotty, 2019; Vinuesa et al., 2016) . The induction of Tfh cells is critical for durable, protective Ab responses (Crotty, 2019) .

Recombinant protein subunit vaccines are often poorly immunogenic and require the addition of adjuvants to enhance the induction of durable protective immune responses (Del Giudice et al., 2018) . Despite ongoing efforts to identify safe adjuvants or novel vaccine platforms that induce strong Tfh cell responses, limited success has been achieved (Linterman and Hill, 2016) . Recent studies have reported negligible or modest Tfh cell generation after immunization of mice and non-human primates with protein antigens formulated with FDA-approved adjuvants such as aluminum hydroxide and MF59 (Liang et al., 2017; Mastelic Gavillet et al., 2015; Olafsdottir et al., 2016) .

These findings may partially explain why currently licensed adjuvants do not support the generation of durable, broadly protective Abs against difficult pathogens such as human immunodeficiency virus 1 (HIV-1), hepatitis C virus, influenza virus, Plasmodium J o u r n a l P r e -p r o o f species and others. This underscores the critical need for new, more effective Tfh cellpromoting adjuvants (Havenar-Daughton et al., 2017; Linterman and Hill, 2016) .

mRNA-based vaccines have recently proven highly effective against infectious diseases (Alameh et al., 2020; Bettini and Locci, 2021; Pardi et al., 2018b) . One of the most promising vaccine platforms comprises nucleoside-modified mRNA encapsulated in lipid nanoparticles (mRNA-LNPs) (Pardi et al., 2015) . Importantly, nucleoside- (Pardi et al., 2018a) . Additionally, mRNA-LNPs induced superior Tfh cell responses compared to an adjuvanted protein subunit vaccine in rhesus macaques (Pardi et al., 2018a) . The mechanisms of Tfh cell induction by mRNA-LNP vaccines is not known. Several studies demonstrated that nucleoside-modified mRNAs do not induce strong inflammatory responses in vitro and in vivo (Kariko et al., 2011; Kariko et al., 2008) . While the effects of LNPs on immune system cell activation have been minimally investigated, a number of studies have indicated that some LNPs could have an intrinsic adjuvant activity (Awasthi et al., 2019b; Shirai et al., 2020; Swaminathan et al., 2016a; Swaminathan et al., 2016b) .

In this report, we demonstrated that the LNP formulation used in previous studies to deliver mRNA (Awasthi et al., 2019a; Freyn et al., 2021; Freyn et al., 2020; Pardi et al., 2018a; Pardi et al., 2017; Pardi et al., 2019; Pardi et al., 2018c; Weissman et al., The nucleoside-modified mRNA-LNP vaccine platform is one of the most promising vaccine modalities and has the ability to induce robust cellular and humoral immune responses, as demonstrated by multiple preclinical (Alameh et al., 2020) and

clinical studies (Jackson et al., 2020; Mulligan et al., 2020; Sahin et al., 2020; Walsh et al., 2020) . The mechanism of action of this vaccine type has not been investigated in detail. The adjuvant activity of nucleoside-modified mRNA-LNPs can stem from the mRNA, from the LNP or from both components. To address this question, we prepared LNPs containing either nucleoside-modified mRNA or no payload (empty LNP, eLNP).

We mixed A/Puerto Rico/8/1934 (PR8, H1N1) influenza virus hemagglutinin recombinant protein (rHA) with mRNA-LNP containing firefly luciferase (Luc)-encoding mRNA or with eLNP equivalent to the same amount of lipid, and administered them intramuscularly (IM) to mice. Animals were bled 4, 8, 12, 16 and 20 weeks post immunization and sera hemagglutination inhibition (HAI) titers were measured, as a simple readout of the quality and magnitude of humoral responses induced by vaccination ( Figure 1A) . We found that rHA + eLNP and rHA + Luc mRNA-LNP induced similarly high PR8 HAI titers at most time points examined, demonstrating that this LNP formulation possesses adjuvant activity. Our study also included a group of mice that was injected with rHA + AddaVax™, an MF59-like adjuvant, as a benchmark. The HAI titers induced by LNP-containing vaccines were an order of magnitude higher compared to those elicited by the AddaVax™-adjuvanted protein vaccine. Luc mRNA did not significantly influence the HAI titers induced by the LNP adjuvant. Non-adjuvanted rHA induced negligible HAI titers, as expected. Of note, LNP-adjuvanted vaccinationinduced HAI titers remained stable for at least 20 weeks ( Figure 1A) . Most licensed J o u r n a l P r e -p r o o f vaccines are delivered IM, but some vaccines are administered intradermally (ID) (i.e.

Fluzone intradermal); thus, we evaluated the various vaccine formats by ID inoculation ( Figure S1 ). Similarly to the IM route, rHA + eLNP vaccine induced long-lasting high PR8 HAI titers after a single immunization, while rHA + AddaVax™ vaccine induced lower HAI titers. In the ID study, we immunized a group of mice with PR8 HA mRNA-LNP and found that the mRNA-LNP vaccine induced comparable PR8 HAI titers to the rHA + eLNP vaccine.

To unequivocally demonstrate that this LNP formulation is, in combination with rHA, a superior adjuvant compared to AddaVax™ at inducing protective Ab responses, we tested these vaccine formats in a challenge experiment. Mice were immunized with rHA alone or supplemented with either AddaVax™ or eLNP, and one group was injected with HA mRNA-LNP. Mice were terminally bled 9 months post immunization, and sera from vaccinated animals were transferred into naïve mice, which were subsequently infected with PR8 influenza virus. HAI titers of sera of immunized mice and serum-transferred mice were determined, and morbidity and mortality of the serum recipient animals were followed daily for two weeks. Mice that received sera from rHAor rHA + AddaVax™-immunized animals started losing weight rapidly (as early as day 2), and were euthanized around day 4, when they reached the humane endpoint of 20% weight loss. However, no or only minimal weight loss could be observed in mice injected with rHA + eLNP or mRNA-LNP vaccine immune sera (Figure 1B-D) .

To further examine the quality of Ab responses, we performed ELISA assays and determined the endpoint dilution titers of IgG, IgG1, IgG2a, IgG2b and IgA induced in the serum 4 weeks after a single immunization with these vaccines. The rHA + eLNP J o u r n a l P r e -p r o o f vaccine induced significantly higher titers of total IgG and all tested IgG subclasses in comparison to rHA + AddaVax™ ( Figure 1E ). Of note, we were also able to detect low levels of IgA, and LNPs outperformed Addavax™ in IgA induction too. Overall, these data indicate that our LNP formulation is capable of inducing functionally variegated Ab responses.

Taken together, these experiments provided proof-of-concept that the LNP used in this study has intrinsic adjuvant property, and is responsible, at least partially, for the potency of nucleoside-modified mRNA-LNP vaccines, and might be repurposed as a standalone adjuvant for the protein subunit vaccine platform.

Since our LNP formulation induced high PR8 HAI titers (Figure 1) , and Tfh cells play a fundamental role in regulating high-quality Ab responses, we hypothesized that LNP-adjuvanted protein vaccines have the capacity to efficiently induce Tfh cell differentiation. In line with our hypothesis, a potent Tfh cell generation was previously reported for nucleoside-modified mRNA-LNP vaccines Lindgren et al., 2017; Pardi et al., 2018a) . To investigate Tfh cell responses, mice were immunized IM or ID with a single dose of rHA + eLNP or rHA + AddaVax™. As a positive control, a group of mice was immunized with PR8 HA mRNA-LNP. Tfh cell responses were examined in the draining lymph nodes (dLNs) by flow cytometry 12 days after vaccination (Figures 2 and S2 ). Animals immunized with rHA + eLNP or HA mRNA-LNP presented higher numbers of CXCR5 + Bcl6 + (Figures 2A-B T follicular regulatory (Tfr) cells are important modulators of Tfh and B cells in response to both foreign Th2 antigens and autoantigens (Clement et al., 2019; Crotty, 2019; Fonseca et al., 2019) . To investigate the balance of Tfh to Tfr cells after immunization with an LNP-adjuvanted vaccine, mice were immunized IM with a single dose of rHA + eLNP or rHA + AddaVax™. Tfh and Tfr cell responses were measured in dLNs at 7, 14, 21 and 28 days post immunization ( Figure S3 ). In agreement with our previous study with nucleoside-modified mRNA-LNP vaccines , we found that (Foxp3 -) Tfh cells peaked around day 7 post immunization and were largely resolved by day 28 post immunization, as further confirmed by a near baseline Tfh/Tfr cell ratio by day 28 post immunization ( Figure S3A and C). Additionally, neither vaccine substantially changed the absolute number of Tfr cells post vaccination at the time points analyzed ( Figure S3B ).

Since Tfh cells provide help to B cells in GCs, we hypothesized that LNPadjuvanted vaccine formats can induce strong GC B cell responses in dLNs. Indeed, rHA + eLNP and HA mRNA-LNP vaccines elicited potent differentiation of GC B cells (Fas + GL7 + ), as measured by flow cytometry (Figures 2E-F and S2H ). Taken together, these data demonstrate that this LNP formulation efficiently induces Tfh and GC B cells after a single IM or ID immunization in mice.

J o u r n a l P r e -p r o o f Durable, affinity-matured Ab responses are associated with induction of GC reactions, giving rise to LLPCs and MBCs (Sallusto et al., 2010) . As we were able to   measure strong Tfh cell, GC B cell and durable Ab responses after a single immunization with LNP-adjuvanted vaccines (Figures 1-2, S1-3) , we hypothesized that this LNP formulation may also efficiently induce LLPC and MBC responses. To directly evaluate this hypothesis, mice were IM or ID immunized with a single dose of rHA + eLNP or rHA + AddaVax™. Antigen-specific LLPC (IgD -/DUMP -/CD138 + /B220 -/PR8 HA + ) and MBC (IgD -/DUMP -/CD138 -/B220 + /CD19 + /CD38 + /GL7 -/PR8 HA + ) absolute numbers were determined 20 weeks post immunization in the bone marrow and spleen, respectively ( Figures 3A-C, S4 ). In agreement with its capacity to efficiently promote the generation of Tfh and GC B cells, the rHA + eLNP vaccine induced stronger PR8

HA-specific LLPC and MBC responses than rHA + AddaVax™.

Ab diversity is critical to recognize a large number of foreign antigens, and can be enhanced by somatic hypermutation (SHM) in the immunoglobulin genes. The process of SHM, coupled with selection for antigen binding, leads to affinity maturation (Griffiths et al., 1984; McKean et al., 1984; Weigert et al., 1970) . Potent neutralizing Abs against certain pathogens (for example HIV and influenza virus) are often highly somatically mutated (Sok et al., 2013; Victora and Wilson, 2015) . Given the critical role of Tfh cells in driving Ab affinity maturation, and our studies demonstrating strong Tfh J o u r n a l P r e -p r o o f and GC B cell differentiation after immunization with LNP-adjuvanted vaccines, we hypothesized that our LNP formulation can elicit Abs with high levels of SHM.

Mice were immunized with eLNP-or AddaVax™-adjuvanted rHA vaccines as described above. Splenic IgD -IgM -HA-binding B cells were sorted ( Figure 3D ) at day 80 post immunization and subjected to bulk sequencing of Ab heavy chain gene rearrangements, as we have described previously (Johnson et al., 2020) . As additional controls, we also sorted and sequenced B cells that were either IgD + (naïve) or HA -IgD -IgM -(class switched). Confirming our previous data ( Figure 3C ), there was a trend towards higher numbers of HA-binding class switched cells ( Figure 3E ) and clones ( Figure 3F ) among the cells sorted from animals that received the rHA + eLNP vaccine compared to the rHA + AddaVax™ vaccine. Because of the relatively low number of HA-binding B cells, we pooled the data from each vaccine group together to evaluate SHM. Mice that received the rHA + eLNP vaccine had fewer unmutated clones than mice that received the rHA + AddaVax™ vaccine (7.6% vs. 33.7%) ( Figure 3G ).

Furthermore, among clones with mutations, those derived from mice that received the rHA + eLNP vaccine had more of them, as evidenced by a right-shifted distribution of SHM that also presented a significantly higher median value (two-tailed Mann-Whitney test, p<0.0001). (Figure 3G ). Among HA-binders, VH1-9, VH7-3 and VH14-3 were used most frequently in both vaccinated groups of mice ( Figure 3H ), in line with previous data from immunized C57BL/6 animals (Johnson et al., 2020) . Taken together, these data suggest that the rHA + eLNP vaccine is more effective than the rHA + AddaVax™ vaccine at generating larger numbers of diverse HA-binding memory B cell clones with higher degree of somatic mutation.

LNPs can be utilized to generate potent mRNA and protein subunit vaccines against SARS-CoV-2 SARS-CoV-2 infection is a serious ongoing pandemic, and vaccines eliciting protective immune responses against the virus will be critical for resolving the current public health crisis (Krammer, 2020) . We and others demonstrated that SARS-CoV-2 nucleoside-modified mRNA-LNP vaccines induced robust, protective immune responses in animals as well as in humans (Bettini and Locci, 2021; Corbett et al., 2020a; Corbett et al., 2020b; Jackson et al., 2020; Laczko et al., 2020; Lederer et al., 2020; Mulligan et al., 2020; Sahin et al., 2020; Walsh et al., 2020; Weissman et al., 2021) . To demonstrate that this LNP formulation can provide adjuvant activity for other antigens, we tested eLNP-and AddaVax™-adjuvanted SARS-CoV-2 spike protein subunit vaccines in mice. Animals were immunized with a single dose of recombinant SARS-CoV-2 spike protein receptor binding domain (rRBD) adjuvanted with eLNP or AddaVax™. As a positive control, a group of mice was immunized with nucleosidemodified RBD mRNA-LNP (Laczko et al., 2020; Lederer et al., 2020) . In line with our previous findings (Laczko et al., 2020; Lederer et al., 2020) , LNP-adjuvanted vaccines elicited durable RBD-specific IgG titers that were significantly higher than the Taken together, we provide evidence that the eLNP-adjuvanted SARS-CoV-2 rRBD vaccine induced potent cellular and humoral immune responses in mice after a single immunization, confirming our findings with rHA + eLNP vaccination.

Lipid nanoparticles are prepared through the mixing of an aqueous solution with an organic solution comprised of an ionizable lipid, cholesterol, helper lipids, and a polyethylene glycol-lipid (PEG-lipid) at different molar ratios (Kulkarni et al., 2019) . To investigate whether the adjuvant effect is due to the composition or physicochemical characteristics of the LNP, we generated empty LNPs with or without the ionizable lipid.

Using dynamic light scattering (DLS), we demonstrated that the average size (Zaverage) of the two formulations were similar, with slightly larger particles formed in the absence of the ionizable lipid ( Figure 5A) . eLNPs with or without the ionizable lipid formed similar, spherical structures, as seen by cryo-electron microscopy (cryo-EM) ( Figure 5B ). In line with the DLS data, the omission of the ionizable lipid had the tendency to create slightly larger particles with typical unilamellar/liposome type structures. In contrast, eLNP with ionizable lipid showed typical electron-dense structures.

To evaluate the adjuvant properties of LNPs with and without the ionizable lipid, mice were immunized with rHA mixed with the two different formats of eLNP, and serum from immunized mice was collected for PR8 HAI assays. In line with our previous studies (Figure 1) , eLNP with the ionizable lipid showed high HAI titers 4 and 8 weeks post vaccine administration ( Figure 5C ). Strikingly, eLNP not containing the ionizable lipid did not possess adjuvant activity, as demonstrated by the absence of HAI activity in sera from mice immunized with these reagents ( Figure 5C ). As physicochemical characterization of eLNPs with and without the ionizable lipid showed similar size distributions by DLS, and spherical structures by cryo-EM, our data suggest that the presence of the ionizable lipid is a critical parameter for providing adjuvant activity to

LNPs.

Next, we generated particles with increasing molar ratio of the ionizable lipid and immunized animals with rHA mixed with these formulations. We found that the molar ratio of the ionizable lipid in the eLNPs slightly increased their adjuvant activity at the highest lipid ratio used, as measured by PR8 HAI titers ( Figure 5D ). Next, we compared the adjuvanticity of this proprietary ionizable lipid to a frequently used (not ionizable) cationic lipid, 1,2-dioleoyloxy-3-(trimethylammonium) propane (DOTAP). DOTAP was formulated into LNP instead of the ionizable lipid with the same ratios of any additional components as the eLNP. In contrast to the ionizable lipid used in eLNP, DOTAP-LNPadjuvanted rHA failed to induce PR8 HAI titers suggesting that not all cationic lipids used for nucleic acid delivery are potent adjuvants in a LNP vaccine format ( Figure 5E ). Next, we investigated whether the cytosolic RNA sensors RIG-I/MDA5 could sense LNP-adjuvanted vaccines. We immunized mitochondrial anti-viral signaling (MAVS)-deficient mice (Mavs -/-) (Loo and Gale, 2011; Seth et al., 2005; Sun et al., 2006) with either HA mRNA-LNP or rHA + eLNP. Mavs -/mice lack MAVS protein, a common adaptor molecule of RIG-I and MDA5 (Loo and Gale, 2011; Seth et al., 2005) .

In contrast to Myd88 -/-, Mavs -/mice showed no significant differences in Tfh cell or GC B cell frequencies and numbers when compared to the control mice ( Figure 6E -F).

Taken together, these data indicate that the 1-methylspeudouridine-modified, cellulose-purified mRNA used in our mRNA-LNP vaccines is sensed by receptors signaling through pathways relying on MyD88, but not MAVS, and suggest a complementary effect of mRNA sensing in the adjuvanticity of mRNA-LNP vaccines. By contrast, our data ruled out a major role played by MyD88-and MAVS-based signaling in the immunostimulatory activity of the LNP component.

To gain further insights into the mechanism of immune activation by LNP-based vaccines, mice were injected with eLNPs formulated with or without the ionizable lipid, lip.) and AddaVax™ elicited lower cytokine and chemokine concentrations ( Figure S7 ).

The differences between AddaVax™ and the ionizable lipid-containing eLNP were particularly noticeable for GM-CSF (34x), IL-1 (22x), IL-5 (17x), IL-6 (≥12x), IP-10 (≥18x), KC (≥20x), LIF (23x), Lix (214x), MIP-2 (≥49x) 4 hours after injection. The signal intensity for several cytokines in the eLNP sample group was above the quantitative range of the plate reader (indicated in Figure S7 ), thus the fold changes for these cytokines may be greater than noted above.

Importantly, we found that our eLNP formulation induced an elevated production of IL-6 ( Figure S7 ), a cytokine that is critical for early Tfh cell differentiation in mice (Crotty, 2019; Vinuesa et al., 2016) . To investigate the role of IL-6 in the adjuvanticity of the LNP, we sought to confirm that IL-6 is induced in dLNs when LNP is injected via the IM route. Mice were immunized with rHA adjuvanted with either AddaVax™ or eLNP and dLNs were collected at 4, 8, 12, 24, and 48 hours post immunization. In agreement with the Luminex data, we found that IL-6 production peaked at 4 hours post immunization and remained elevated for at least 24 hours before beginning to decline by 48 hours (Figure 7A ).

Since IL-6 has been shown to be an early regulator of Tfh cell differentiation in mice (Choi et al., 2013) , we first investigated if LNP-induced IL-6 is indeed a relevant driver of Tfh cell induction 5 days after immunization. Mice received an IL-6 blocking J o u r n a l P r e -p r o o f mAb (anti-IL-6 mAb) or an isotype control mAb one day prior to immunization with rHA + eLNP and then every other day post immunization for the duration of the study.

anti-IL-6 mAb in comparison to isotype mAb-treated animals ( Figure 7B ). To confirm the role of IL-6 in Tfh cell differentiation and function, we immunized IL-6-deficient mice (Il6 -/-) or strain-matched control mice with HA mRNA-LNP or rHA + eLNP, and analyzed

Tfh and GC B cell responses 12 days post immunization. We observed that, with either We assume the limited size of our test group may have been the reason for this. In addition to a decrease in Tfh cells, total and antigen-specific GC B cell frequencies and absolute numbers were also reduced ( Figure 7E -F) in the Il6 -/mice in both the HA mRNA-LNP and rHA + eLNP groups. These data indicate an impairment of the GC response supported by this LNP formulation in the absence of IL-6.

Taken together, these data show that the ionizable lipid-containing LNP drives the production of IL-6 in dLNs of mice, and that LNP-mediated IL-6 production is critical for the induction of Tfh cells in response to both mRNA and recombinant protein vaccines adjuvanted with LNPs. profiles in studies such as these.

As nucleoside-modified mRNA-LNP vaccines are being deployed in humans at a large scale for the first time ever, studies examining the mechanism of action become critical to improve and fine tune efficacy of such vaccines in the future. Both licensed COVID-19 mRNA-LNP vaccines contain LNPs with ionizable cationic lipids. Our study suggests that the high efficacy of these vaccines might, at least partially, stem from the potent adjuvant properties of the ionizable lipid component of LNPs. Importantly, we demonstrate here that the empty LNP formulation used in our study is endowed with an intrinsic ability to promote the secretion of IL-6 in mice. IL-6 levels were elevated 4 hours after LNP injection and waned by 48 hours. LNP-induced IL-6 appeared to be largely responsible for the induction of Tfh cells, as supported by the severe reduction of Tfh cell generation after rHA + eLNP immunizations in IL-6-deficient mice or in animals treated with an IL-6 blocking mAb in comparison to wild type or isotype mAb-treated controls, respectively. IL-6 is a well-established pro-Tfh cell-inducing factor (Crotty, 2014) and an important player of early Tfh cell differentiation. By signaling through the IL-6 receptor complex, this cytokine promotes the expression of B-cell lymphoma 6 (Bcl6), the Tfh cell lineage-defining transcription factor in activated CD4 T cells (Nurieva et al., 2009) . Furthermore, IL-6 is the most potent inducer of the Tfh cell-signature cytokine IL-21 in mice (Crotty, 2014) . Of note, IL-6 is not a universally required regulator of Tfh cell biology; it appears to be only marginally important for murine Tfh cell differentiation in certain viral infections or protein immunizations (Eddahri et al., 2009; Eto et al., 2011; Poholek et al., 2010) , while relevant in others (De Giovanni et al., 2020;  J o u r n a l P r e -p r o o f Riteau et al., 2016) . A key determinant for IL-6 involvement in Tfh cell differentiation in diverse infection/immunization models is the timing of IL-6 induction (De Giovanni et al., 2020) . VSV infection has been shown to cause an early peak of IL-6 that, in turn, promotes Tfh cell differentiation. Conversely, lymphocytic choriomeningitis virus (LCMV) drives a more modest and delayed IL-6 production that does not have any major role in shaping Tfh cell responses. Since we observed a noticeable IL-6 production as early as 4 hours after the injection of eLNP and a reduced Tfh cell differentiation 5 days after immunization with rHA + eLNP in mice where IL-6 was blocked, it is likely that, similar to what was described by Iannacone and colleagues during VSV infection (De Giovanni et al., 2020) , an "early" IL-6 induction by the LNP accounts for a robust Tfh cell differentiation also in our study.

An aspect that still remains to be determined is how the LNP triggers IL-6 production in a prompt and efficient fashion. Our work indicates that this LNP synthesis, which could also trigger PAMP sensing mechanisms and contribute to excessive inflammation (Hur, 2019) . Our data indicate that the combination of nucleoside modification and cellulose purification might not completely abolish the recognition of mRNA or its degradative products by one or multiple TLRs, and that this residual capacity to promote TLR signaling is an active component of the ability of mRNA-LNP to foster GC responses. An alternative explanation for the observed phenotype could also be that, instead of (or beside) being sensed by TLRs, the 1methylpseudouridine-modified mRNA and/or its degradative products trigger alternative sensing mechanisms, which ultimately support the generation of Tfh cells via the production of cytokines binding to IL1R family, which also signals through the adaptor protein MyD88 (Martin and Wesche, 2002) .

In summary, we believe that our study represents a major advancement in the field of infectious disease vaccines, because it provides insights on the mechanism of action of nucleoside-modified mRNA-LNP vaccines and suggest that currently approved protein subunit vaccines may be improved by using LNPs as adjuvants.

It is worth noting that the potential role of IL-6 in human Tfh cell biology is less evident than in mice. In humans, IL-21 production by CD4 + T cells is predominantly regulated by IL-12 (Locci et al., 2016; Schmitt et al., 2009) , and the addition of IL-6 to human CD4 + T cells in vitro does not seem to induce the expression of Tfh-signature markers such as CXCR5 or Bcl6 (Schmitt et al., 2014) . On the other hand, inborn errors J o u r n a l P r e -p r o o f of immunity leading to reduced STAT3 signaling capacity in humans are associated with reduced frequencies of circulating Tfh cells (Ma et al., 2012; Ma et al., 2015) , suggesting a possibly unappreciated role for IL-6 in human Tfh cell differentiation (as IL-6 is one of the cytokines signaling via STAT3). Since SARS-CoV-2 nucleoside-modified mRNA-LNP vaccines promote robust GC B cell and Tfh cell responses in humans (Lederer et al., 2021; Mudd et al., 2021; Turner et al., 2021) , we argue that a similar pro-Tfh cell inducing activity is also present in humans, and that the mechanism could also likely rely on LNP-induced IL-6 activity, as supported by a recently described STAT3-signature in T cells of SARS-CoV-2-vaccinated individuals (Arunachalam et al., 2021) . Alternatively, LNPs might be capable of inducing additional cytokines that have been described as potent regulators of human Tfh cell differentiation such as IL-12, activin A or TGF-beta (Locci et al., 2016; Schmitt et al., 2014; Schmitt et al., 2009) .

Future studies will address these important questions.

conjugated tetramer (HNTNGVTAACSHE) used in this study and the Human Immunology Core facility for assistance with immunoglobulin gene rearrangement sequencing (with infrastructure support from P30 CA016520 and P30-AI 0450080). We Mann-Whitney U test was conducted. **P  0.01, ***P  0.001. See also Figure S4 . Figure S7 .

Further information and requests for supporting data, resources, and reagents should be directed to and will be fulfilled upon request by the Lead Contact, Norbert Pardi (pnorbert@pennmedicine.upenn.edu).

Reagents from this study are available upon request. (Corrie et al., 2018) .

 This paper does not report original code.

 Raw data are available for reanalysis from the lead contact upon request.

Eight-week-old BALB/c mice were purchased from Charles River Laboratories and The Jackson Laboratory and were housed either in a conventional or a Specific Pathogen were synthesized and cloned into an mRNA production plasmid as described (Freyn et al., 2020) . mRNA production was performed as described (Freyn et al., 2020) . Briefly, mRNAs were produced to contain 101 nucleotide-long poly(A) tails. m1Ψ-5'triphosphate instead of UTP was used to generate modified nucleoside-containing mRNA. Capping of the in vitro transcribed mRNAs was performed co-transcriptionally using the trinucleotide cap1 analog, CleanCap. mRNA was purified by cellulose purification, as described (Baiersdorfer et al., 2019) . All mRNAs were analyzed by agarose gel electrophoresis and were stored frozen at -20°C. Cellulose-purified m1Ψ-J o u r n a l P r e -p r o o f containing RNAs were encapsulated in LNPs using a self-assembly process as previously described wherein an ethanolic lipid mixture of ionizable cationic lipid, phosphatidylcholine, cholesterol and polyethylene glycol-lipid was rapidly mixed with an aqueous solution containing mRNA at acidic pH (Maier et al., 2013) . The LNP formulation used in this study is proprietary to Acuitas Therapeutics; the proprietary lipid and LNP composition are described in US patent US10,221,127. As the DOTAPcontaining LNP could not be easily concentrated after the self-assembly process, the DOTAP-LNP was made using an extrusion process (Mui et al., 2003) . The lipids (DOTAP, cholesterol, DSPC, PEG-lipid) were first solubilized in chloroform. The chloroform was removed using a stream of nitrogen gas and the lipid film was put under vacuum for 2 h to remove residual solvent. The lipid film was hydrated in PBS, freezethawed 5 times using liquid nitrogen and a 60°C water bath, and then extruded 10 times through 80 nm pore-sized filters. The RNA-loaded and empty particles were characterized and subsequently stored at -80°C at an RNA concentration of 1 μg μl -1 (in the case of loaded particles) and total lipid concentration of 30 μg μl -1 (both loaded and empty particles). The mean hydrodynamic diameter of mRNA-LNPs was ~80 nm with a polydispersity index of 0.02-0.06 and an encapsulation efficiency of ~95%. Two or three batches from each mRNA-LNP formulations were used in these studies and we did not observe variability in vaccine efficacy.

The PR8 HA recombinant protein and the SARS-CoV-2 RBD protein used for vaccine studies were purchased from Sino Biological.

The PR8 HA and RBD proteins used for generating fluorescently-labeled probes for B cell analyses and PR8 HA ELISA studies were produced as described previously Margine et al., 2013; Stadlbauer et al., 2020) . The RBD protein used for ELISA was purchased from GenScript.

Fluorescently-labeled recombinant RBD protein was prepared as previously described (Laczko et al., 2020; Lederer et al., 2020) . Briefly, rRBD was independently conjugated to either PE or AlexaFluor 647 using the Lightning-Link® R-Phycoerythrin (R-PE) and

Lightning-Link (R) Rapid Alexa Fluor 647 according to manufacturer's instructions. To create fluorescently labeled RBD and HA tetramers, recombinant RBD or HA was biotinylated using the EZ-Link Micro Sulfo-NHS-Biotinylation Kit. Streptavidinconjugated Alexa Fluor 647, Alexa Fluor 488, or Brilliant Violet 421 were then added at a 6:1 molar ratio (biotinylated-protein to streptavidin-conjugate). Specifically, after the volume of fluorochrome needed to achieve a 6:1 molar ratio was determined, the total volume of fluorochrome was split into 10 subaliquots. These subaliquots were then added, on ice, to the biotinylated protein and mixed by pipetting every 10 minutes (for a total of 10 additions).

The hydrodynamic diameter (Z-average size) of LNPs (with and without mRNA) was measured at 25°C by DLS using a Zetasizer Nano ZS instrument (Malvern Instruments Ltd) equipped with a solid-state HeNe 633nm laser at a scattering angle of 173 o . LNP J o u r n a l P r e -p r o o f samples formulated at 1 mg/ml mRNA (or an equivalent of 1 mg/ml for empty LNP)

were diluted 1:500 using sterile phosphate-buffered saline before determination of size/PDI. The Z-average is represented as diameter in nm +/-width of distribution.

eLNPs with and without ionizable lipid were vitrified using Vitrobot Mark IV System (FEI/Thermo Scientific), and frozen grids were imaged with 300 kV Titan Krios Cryo-TEM with a Falcon III camera (FEI/Thermo Scientific). Images were analyzed using ImageJ. Between 200 to 300 particles were manually measured to determine the diameter of the LNPs. The size of the LNPs are represented as diameter in nm +/standard deviation.

BALB/c mouse immunizations: Vaccines were administered via the intramuscular (IM) route into the gastrocnemius muscle, or the intradermal (ID) route across two sites localized towards the base of the tail using a 3/10cc 29½G insulin syringe (Covidien).

Mice were immunized with one of the following combinations: 10 µg recombinant PR8 HA (rHA), 10 µg rHA + 30 µg Luc mRNA-LNP (containing 30 µg mRNA and 900 µg total lipid), 10 µg rHA or rRBD + Addavax™ according to manufacturer's instructions (equal volumes of protein and AddaVax TM were mixed), 10 µg rHA or rRBD + eLNP (total lipid content: 900 µg; equivalent to lipid content of 30 µg mRNA-LNP), or 10 µg PR8 HA or RBD mRNA-LNP.

In the IL-6 Ab blockade experiments, mice were given 0.5 mg of anti-IL6 antibody or isotype antibody intraperitoneally (IP) one day prior to immunization and 0.25 mg every other day following immunization.

Targeted mutant mouse immunizations: Mice were immunized IM in the gastrocnemius muscle. Mice were immunized with either 30 µg PR8 HA mRNA-LNP or 30 µg rHA + eLNP (total lipid content equivalent to 30 µg mRNA-containing mRNA-LNP).

Mice were isoflurane-anesthetized and blood was collected through the retro-orbital route. Serum was separated from blood following an incubation period of 30 minutes at room temperature, and samples were centrifuged at 10 000 g for 5 minutes in a nonrefrigerated Eppendorf 5424 centrifuge. Separated serum was stored at -20°C.

8-week-old BALB/c mice were immunized ID with 10 μg rHA, 10 μg rHA + Addavax™, 10 μg rHA + eLNP (30 μg mRNA-LNP equivalent) or 10 μg HA mRNA-LNP. Animals were terminally bled 9 months post-immunization, and HAI titers were determined. 400 μl of each individual immune sera was injected IP into naïve recipient mice. Two hours after serum transfer, recipient mice were put under isoflurane anesthesia, and blood was collected for post transfer HAI titer determination. Then, mice were infected with 5000 focus forming units (FFU) of mouse-adapted A/Puerto Rico/8/1934 influenza virus (see IAV LD in (Tapia et al., 2013) ) diluted in a final volume of 40 μl PBS. Viral solution was applied dropwise to nasal orifice, and was inhaled by serum-transferred mice.

Weight loss was followed daily for 14 days. Animals were euthanized when they lost 20% of their starting bodyweight, as per IACUC protocol.

Sera were heat-inactivated (55°C) for 30 minutes, spun down at 11000 rpm for 2 minutes, and diluted 1:20 in PBS, then serially diluted 1:2 in 50 µl in 96-well U-bottom plates (lowest concentration: 1:2560) using a multichannel pipette. Then, four hemagglutinating doses of A/Puerto Rico/8/1934 virus was added in the same volume as diluted sera. Finally, 12.5 μl of turkey erythrocyte solution -washed twice in phosphate buffered saline and diluted to a final concentration of 2% (v/v) -was added, and gently mixed with the sera-virus solution (final volume of 125 µl). Samples were incubated for 45 minutes at room temperature, after which the plates were turned on the side for one minute, then scanned on a regular office scanner. HAI titers were determined as the highest dilution of the sample that inhibited four agglutinating doses of the influenza virus. Inhibition of agglutination was observed as the blood forming a "tear drop" shape.

Lymph nodes were collected at specific time points and snap-frozen in a mixture of isopropanol and dry ice and stored at -80°C until use. Frozen tissues were cut on dry ice, weighed (~20 mg), and disrupted using the TissueLyzer® II system (Qiagen).

Tissues were disrupted using 5 mm steel beads ( ELISA, whole lymph nodes were resuspended in lysis buffer (as above) prior to homogenization (as above). Lysates were cleared by centrifugation (2270 g, 30 minutes, 4°C), transferred to new tubes, and stored at -80°C until use. An aliquot was diluted 1:100 in PBS and total protein content of the lysate sample was determined using the Pierce microBCA protein assay kit or measured undiluted using the Pierce BCA protein assay kit for the IL-6 ELISA.

Tissue lysate collected at 4 and 24 hours post administration of test articles were assayed for the induction of a 32 pro-inflammatory cytokine panel (MCYTOMAG-70K;

including TNF-α, IL-1β, IL-6, KC, and IFN-γ) using the Luminex® technology. Plates were designed using the Milliplex® assay builder (Millipore-Sigma) and subjected to the manufacturer's quality control. For each plate, a standard curve was prepared by diluting the Milliplex ® Pro Mouse Cytokine Standard 32-Plex in the Milliplex ® in standard diluent followed by 4-fold serial dilutions from 1:4 to 1:65536 in the same diluent.

Samples were thawed on ice, cleared by centrifugation (10,000 g, 10 minutes, 4°C), For each plate, an IL-6 standard curve was prepared by dissolving lyophilized IL-6 in lysis buffer at 500 pg/ml and then performing a 2-fold serial dilution to ~4 pg/ml. Tissue J o u r n a l P r e -p r o o f and AF647. IgD + follicular B cells, HA + IgD -IgMmemory, and HA -IgD -IgM -B cells were sorted using a BD FACS Aria II sorter (see Figure 3D for gating strategy). Staining panel details in Table S2 .

Sample processing, amplification, and library preparation: mouse spleens were harvested at day 80 post immunization, and single-cell suspension was prepared in RPMI-1640 media following physical tissue homogenization. Genomic DNA was extracted from sorted cells using the Qiagen Gentra DNA purification kit following the manufacturer's recommendations. Amplification and sequencing of Ab heavy chain gene rearrangements were performed as described previously (Johnson et al., 2020) .

Libraries were pooled at equimolar ratios and loaded onto an Illumina MiSeq in the Human Immunology Core Facility at the University of Pennsylvania, and subjected to pair-end sequencing (2x300 bp) using the Illumina MiSeq Reagent kit.

Processing and analysis of sequencing data: raw sequencing data in FASTQ format were processed with pRESTO version 0.5. 10 (Vander Heiden et al., 2014) . Paired reads were aligned and sequences were subsequently subjected to quality filtering as described previously (Johnson et al., 2020) . IgBLAST was used for gene identification and ImmuneDB v0.29.9 was used for clonal inference (Rosenfeld et al., 2018) . After gene identification, sequences were trimmed to IMGT position 20 to remove 5' primer sequences. Sequences sharing the same VH gene, JH gene, and 85% CDR3 aminoacid similarity were then grouped into clones and clones averaging less than 85% IGHV nucleotide identity were excluded from further analysis to minimize sequencing artifacts.

J o u r n a l P r e -p r o o f

The mechanism of action of nucleoside-modified mRNA-LNP vaccines is unknown. 

Toll-like receptor signalling

Messenger RNA-Based Vaccines Against Infectious Diseases

A serological assay to detect SARS-CoV-2 seroconversion in humans

Systems vaccinology of the BNT162b2 mRNA vaccine in humans

Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes

Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants

A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA

SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines (Basel) 9

Cutting edge: STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation

Follicular regulatory T cells control humoral and allergic immunity by restraining early B cell responses

SARS

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

iReceptor: A platform for querying and analyzing antibody/B-cell and T-cell receptor repertoire data across federated repositories

T follicular helper cell differentiation, function, and roles in disease

T Follicular Helper Cell Biology: A Decade of Discovery and Diseases

Spatiotemporal regulation of type I interferon expression determines the antiviral polarization of CD4(+) T cells

Correlates of adjuvanticity: A review on adjuvants in licensed vaccines

A Balancing Act: MDA5 in Antiviral Immunity and Autoinflammation

Strategies to guide the antibody affinity maturation process

Interleukin-6/STAT3 signaling regulates the ability of naive T cells to acquire B-cell help capacities

IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation

T follicular regulatory (Tfr) cells: Dissecting the complexity of Tfr-cell compartments

Antigen modifications improve J o u r n a l P r e -p r o o f nucleoside-modified mRNA-based influenza virus vaccines in mice

A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice

Somatic mutation and the maturation of immune response to 2-phenyl oxazolone

Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem

Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms

Double-Stranded RNA Sensors and Modulators in Innate Immunity

Exploiting Mucosal Immunity for Antiviral Vaccines

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

The Transcription Factor T-bet Resolves Memory B Cell Subsets with Distinct Tissue Distributions and Antibody Specificities in Mice and Humans

Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA

Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability

SARS-CoV-2 vaccines in development

Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics

A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice

SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation

Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. medRxiv

Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake

Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells

Can follicular helper T cells be targeted to improve vaccine efficacy?

Activin A programs the differentiation of human TFH cells

Immune signaling by RIG-I-like receptors

Functional STAT3 deficiency compromises the generation of human T follicular helper cells

Monogenic mutations differentially affect the quantity and quality of T follicular helper cells in patients with human primary immunodeficiencies

Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics

Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system

Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family

MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life

SARS-CoV-2 mRNA vaccination elicits robust and persistent T follicular helper cell response in humans

Extrusion technique to generate liposomes of defined size

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Bcl6 mediates the development of T follicular helper cells

The history of Toll-like receptorsredefining innate immunity

Comparative Systems Analyses Reveal Molecular Signatures of Clinically tested

Nucleoside-modified mRNA J o u r n a l P r e -p r o o f vaccines induce potent T follicular helper and germinal center B cell responses

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

mRNA vaccines -a new era in vaccinology

Characterization of HIV-1

Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques

Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies

Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes

In vivo regulation of Bcl6 and T follicular helper cell development

RIG-I-like receptors: their regulation and roles in RNA sensing

Water-in-Oil-Only Adjuvants Selectively Promote T Follicular Helper Cell Polarization through a Type I IFN and IL-6-Dependent Pathway

ImmuneDB, a Novel Tool for the Analysis, Storage, and Dissemination of Immune Repertoire Sequencing Data

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

From vaccines to memory and back

The cytokine TGF-beta co-opts signaling via STAT3-STAT4 to promote the differentiation of human TFH cells

Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12

Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3

Lipid Nanoparticle Acts as a Potential Adjuvant for Influenza Split Vaccine without Inducing Inflammatory Responses

The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies

Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup

The specific and essential role of MAVS in antiviral innate immune responses

A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens

A Tetravalent Sub-unit Dengue Vaccine and Non-Human Primates

Defective viral genomes arising in vivo provide critical danger signals for the triggering of lung antiviral immunity

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses

pRESTO: a toolkit for processing highthroughput sequencing raw reads of lymphocyte receptor repertoires

Germinal centers

Germinal center selection and the antibody response to influenza

Follicular Helper T Cells

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Variability in the lambda light chain sequences of mouse antibody

D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization